Nishitsuji Hironori, Kohara Michinori, Kannagi Mari, Masuda Takao
Department of Immunotherapeutics, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.
J Virol. 2006 Aug;80(15):7658-66. doi: 10.1128/JVI.00078-06.
Small interfering RNA (siRNA) could provide a new therapeutic approach to treating human immunodeficiency virus type 1 (HIV-1) infection. For long-term suppression of HIV-1, emergence of siRNA escape variants must be controlled. Here, we constructed lentiviral vectors encoding short-hairpin RNAs (shRNA) corresponding to conserved target sequences within the integrase (int) and the attachment site (att) genes, both of which are essential for HIV-1 integration. Compared to shRNA targeting of the HIV-1 transcription factor tat (shTat), shRNA against int (shIN) or the U3 region of att (shU3) showed a more potent inhibitory effect on HIV-1 replication in human CD4+ T cells. Infection with a high dose of HIV-1 resulted in the emergence of escape mutants during long-term culture. Of note, limited genetic variation was observed in the viruses resistant to shIN. A combination of shINs against wild-type and escape mutant sequences had a negative effect on their antiviral activities, indicating a potentially detrimental effect when administering multiple shRNA targeting the same region to combat HIV-1 variants. The combination of shIN and shU3 att exhibited the strongest anti-HIV-1 activity, as seen by complete abrogation of viral DNA synthesis and viral integration. In addition, a modified long-hairpin RNA spanning the 50 nucleotides in the shIN target region effectively suppressed wild-type and shIN-resistant mutant HIV-1. These results suggest that targeting of incoming viral RNA before proviral DNA formation occurs through the use of nonoverlapping multiple siRNAs is a potent approach to achieving sustained, efficient suppression of highly mutable viruses, such as HIV-1.
小干扰RNA(siRNA)可为治疗人类免疫缺陷病毒1型(HIV-1)感染提供一种新的治疗方法。为了长期抑制HIV-1,必须控制siRNA逃逸变体的出现。在此,我们构建了慢病毒载体,其编码对应于整合酶(int)和附着位点(att)基因内保守靶序列的短发夹RNA(shRNA),这两个基因对于HIV-1整合都是必不可少的。与靶向HIV-1转录因子tat的shRNA(shTat)相比,针对int的shRNA(shIN)或att的U3区域的shRNA(shU3)对人类CD4+T细胞中HIV-1复制的抑制作用更强。高剂量HIV-1感染导致长期培养过程中出现逃逸突变体。值得注意的是,在对shIN耐药的病毒中观察到有限的基因变异。针对野生型和逃逸突变体序列的shIN组合对其抗病毒活性有负面影响,这表明在使用多个靶向同一区域的shRNA对抗HIV-1变体时可能产生有害影响。shIN和shU3 att的组合表现出最强的抗HIV-1活性,这可通过完全消除病毒DNA合成和病毒整合来体现。此外,跨越shIN靶区域50个核苷酸的修饰长发夹RNA有效抑制了野生型和对shIN耐药的突变体HIV-1。这些结果表明,在原病毒DNA形成之前通过使用非重叠的多个siRNA靶向进入的病毒RNA是实现对高度可变病毒(如HIV-1)进行持续、有效抑制的有效方法。